Construction of the new 189,500-square-foot facility is underway and WuXi expects the site to be operational in 2025 with GMP release in 2026.

According to WuXi, the expansion of the facility will add another 200 employees to the current 400 in the USA.

Chris Chen, CEO of WuXi Biologics, said: “The new commercial capacity in Worcester, Massachusetts represents a key part of our global biomanufacturing network, reflecting our commitment to continuously strengthen our capabilities in line with anticipated market and client needs.”

Last year, WuXi Biologics launched its first Boston Research Service Center, the company’s fourth site in the US after its clinical manufacturing facility in New Jersey and process development and characterization laboratories in Pennsylvania.